HOME >> BIOLOGY >> NEWS
Gene vaccine for Alzheimer's disease shows promising results

DALLAS Dec. 13, 2004 UT Southwestern Medical Center at Dallas researchers have found a way of stimulating the immune systems of mice to fight against amyloid proteins that cause the devastating plaques that are characteristic of Alzheimer's disease.

For years scientists have examined the possibility of using a protein-based vaccine to slow the progression of the disease in its early stages. UT Southwestern researchers have created a gene-based vaccine aimed at stimulating the immune systems of mice to potentially fight off plaque-causing amyloid protein in the brain.

Their findings appear in today's issue of the Archives of Neurology.

"Previous Alzheimer's vaccines were protein-based," said Dr. Baoxi Qu, the study's lead author and assistant professor in the Center for Biomedical Inventions and internal medicine. "We wanted to try a DNA-based genetic vaccine instead to see if we could enhance the immune response."

Although prior studies of amyloid protein vaccination had shown some slowing in the plaque buildup, negative side effects also occurred in a handful of patients. Some had autoimmune responses that caused encephalitis.

The key in the UT Southwestern study was finding another way to vaccinate patients without stimulating the body's own immune cytotoxic T cells, said Dr. Roger Rosenberg, a study author and director of the Alzheimer's Disease Center.

"This dilemma was discussed with my colleagues, and we decided to try vaccination with an amyloid gene, rather than the amyloid protein vaccine," said Dr. Rosenberg.

The UT Southwestern researchers vaccinated mice with a "gene gun." The gene gun and gene-vaccination technologies were invented by Dr. Stephen Albert Johnston, director of the Center for Biomedical Inventions and senior author of the latest study.

"We have been developing ways to use gene-immunization to manipulate the immune response," Dr. Johnston said. "This study was
'"/>

Contact: Katherine Morales
katherine.morales@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
14-Dec-2004


Page: 1 2

Related biology news :

1. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
2. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
3. Handicapping tuberculosis may be the way to a better vaccine
4. Developing a more effective vaccine for tuberculosis
5. New target for HIV/AIDS drugs and vaccine discovered
6. Genomic analysis uncovers new targets for HIV vaccine
7. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
8. Universal flu vaccine being tested on humans
9. From clinical cancer research: rethinking therapeutic cancer vaccine trials
10. Paving the way toward a vaccine against Alzheimers disease
11. Mucosal-surface immune function discoveries could boost vaccine research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene vaccine for Alzheimer disease shows promising results

(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on ... current state of the global Propanol market with a focus on the Chinese situation. ... Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... As part of its 2015 growth plan ... and technical service business units, Whitehouse Laboratories is pleased to announce that ... adjacent to the Container Center of Excellence and will be strictly dedicated to basic USP ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
Cached News: